Requires DOC and county correctional facilities to provide certain inmates with medication-assisted treatment.
Impact
The enactment of S1845 is expected to significantly impact correctional health care by establishing a structured approach to manage and treat substance use disorders within the prison population. It aims to enhance the quality of health care available to inmates, thereby potentially reducing recidivism rates associated with substance dependency. The requirement for comprehensive evaluations and the availability of MAT are crucial steps toward reintegrating inmates into society healthier and more equipped to handle their conditions.
Summary
Senate Bill S1845 in New Jersey is a legislative measure aimed at providing medication-assisted treatment (MAT) for inmates whose initial evaluations indicate they are struggling with substance use disorders. This bill mandates that both state and county correctional facilities evaluate incoming inmates to determine their need for MAT. If deemed necessary, inmates can voluntarily opt to participate in the treatment, which combines medications approved by the FDA with counseling and behavioral therapies.
Contention
While supporters of S1845 argue that it represents a progressive move toward treating addiction as a health issue rather than solely a criminal one, concerns exist regarding the implementation of such programs in a correctional setting. Critics may argue about the adequacy of resources required to deliver these treatments effectively within prisons, along with potential issues regarding consent and the voluntary nature of the treatment amidst a coercive environment. These debates highlight the tension between rehabilitation and punishment within the criminal justice system.
Imposes requirements on video visitation service contracts for inmates in certain correctional facilities; requires correctional facilities to allow contact visits.
Imposes requirements on video visitation service contracts for inmates in certain correctional facilities; requires correctional facilities to allow contact visits.
Residential Substance Use Disorder Treatment Act of 2023 This bill revises and reauthorizes through FY2027 grants for residential substance use disorder treatment programs at state and local correctional and detention facilities. Among the revisions, the bill replaces statutory references to substance abuse with substance use disorder, specifies that the term residential substance use disorder treatment program includes a medication-assisted treatment program, requires the chief medical officer or other staff overseeing a program to complete training on the science of addiction and the latest research and clinical guidance on treating substance use disorders in criminal justice settings, and allows people who are awaiting trial or in pretrial detention to participate in the programs.
Requiring licensure of outpatient substance use disorder treatment facilities and relative to complaint investigation of treatment facilities by the department of health and human services office of the ombudsman and making an appropriation therefor.
Establishing the Nonnarcotic Medication Substance Use Disorder Treatment Program; in organization and jurisdiction of courts of common pleas, providing for court assessments for substance use disorder treatment; in other criminal provisions, further providing for supervisory relationship to offenders; and, in Pennsylvania Board of Probation and Parole, further providing for supervisory relationship to offenders.